LakeShore Biopharma Co., Ltd LSB
At closeSep 19, 2025, 4:00 PM EDT
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 25.84M
- Revenue (ttm)
- 573.42M
- Profit margin
- -75.59%
- Shares out
- 19.08M
- Forward P/E
- -12.28
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 658.32K
- Avg volume
- 83.63K
- Open
- 0.7899
- Previous close
- 0.627
- Day's range
- 0.627 – 0.7899
- 52-week range
- 0.5743 – 0.855
- Beta
- 0.74
- Earnings date
- Jan 27, 2025
Key statistics
- Enterprise value
- 234.59M
- PEG ratio
- 0.00
- Price / sales
- 0.10
- Price / book
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.70%
- Free cash flow
- -216.49M
- Total cash
- 246.35M
- Total debt
- 424.46M
- Return on equity
- -65.99%
- Short % of float
- 0.84%
- 50-day average
- 2.77
- 200-day average
- 5.63
Next earnings
Jan 27, 2025
Expected Jan 27, 2025. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 27, 2025 | Sep 1, 2024 | -0.80 | — | — | — |
| Oct 1, 2024 | Jun 1, 2024 | -0.09 | — | — | — |
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- ysbiopharm.com
News
LSB Industries, Inc. Reports Operating Results for the 2026 Third Quarter 
LSB Industries, Inc. Schedules 2026 Third Quarter Results Release for Wednesday, October 28th and Conference Call for Thursday, October 29th 
LSB Industries, Inc. to Participate in Upcoming Investor Conferences 
LSB Industries: Why Cost Advantage Makes It A Buy 
LSB Industries, Inc. Reports Operating Results for the 2026 Second Quarter 
LSB Industries, Inc. Schedules 2026 Second Quarter Results Release for Wednesday, July 29th and Conference Call for Thursday, July 30th 
LSB Industries: Ongoing Margin Execution Is Not Being Appreciated Enough 
LSB Industries Reaches Agreement Establishing a Pathway to 100% Ownership of El Dorado CCS Project 
LSBCF Investors Have Opportunity to Join LakeShore Biopharma Co., Ltd Fraud Investigation with the Schall Law Firm 
LSB Industries, Inc. Reports Operating Results for the 2026 First Quarter
Your note
Sign in to keep a note on LSB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 0.10% | 116,507 | 357.68K | Sep 29, 2024 |
| HHLR Advisors, LTD | 0.06% | 75,179 | 230.80K | Sep 29, 2024 |
| FIL LTD | 0.05% | 61,548 | 188.95K | Sep 29, 2024 |
| Superstring Capital Management LP | 0.03% | 30,792 | 94.53K | Sep 29, 2024 |
| Barclays Plc | 0.02% | 24,758 | 76.01K | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 0.01% | 9,381 | 28.80K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 1,361 | 4.18K | Oct 30, 2024 |